CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 464 enrolled
Drug / intervention
Saliva Assaydevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04579549
NCT04579549N/ACompleted
CompareCT.gov

Repeat Saliva Testing for SARS-CoV-2 Using RT-LAMP Assay

University of Wisconsin, Madison·interventional·Posted Oct 8, 2020·Updated Jan 20, 2022

In Brief

A clinical study evaluating Saliva Assay for COVID-19 and Sars-CoV-2. Completed, enrolled 464 participants across 1 site.

Detailed Summary

The purpose of this research study is to determine if high-frequency, rapid turn-around SARS-CoV-2 surveillance testing with this assay is feasible and able to be optimized to enable isolation and follow-up diagnostic testing. This test will be performed at various locations in the Madison, Wisconsin area using a mobile laboratory or standard lab space for processing. Saliva samples can be collected and processed at these locations or participants can self-collect at home and drop their samples off at designated locations for same day processing. Up to 10000 participants will be recruited for this study.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCOVID-19, Sars-CoV-2
CountriesUnited States
CollaboratorsNational Institutes of Health (NIH)

Timeline

N/ACompletedFinished
202120222023202420252026
First PostedOct 8, 2020
Enrollment StartSep 29, 2020
Primary CompletionMar 31, 2021
TodayJul 2, 2026
Enrollment to primary: 6 monthsPosted 5.7 years ago

Interventions

Saliva Assaydevice

saliva assay test for high concentrations of SARS-CoV-2